Participated · Series F · Jul 2020

CF PharmTech is a fully integrated specialty pharmaceutical company that develops and manufactures inhalation products and respiratory drugs. The company focuses on treatments for respiratory diseases and operates facilities for drug development and production. It raised a US$50M Series F financing to support its programs. The company followed a US$90M Series E in January 2020; together those rounds amount to nearly US$140M of equity investment within six months. CF PharmTech says it will use the Series F proceeds to accelerate commercialization of its inhalation products. The company positions itself to provide affordable, high-quality respiratory drugs globally. CF PharmTech is a pharmaceutical company dedicated to respiratory health, with state-of-the-art R&D and manufacturing facilities for inhalation products. The company has built a pipeline of more than 20 products aimed at China and global markets. It raised a $90M Series E to advance its product pipeline. The firm intends to use the funds to bring products in its pipeline to market. CF PharmTech operates from Shuzhou, China, and emphasizes inhalation therapeutics and related manufacturing capabilities. The article does not disclose revenue or user metrics. CF PharmTech is a Suzhou, China-based specialty pharmaceutical company focused on the development, manufacturing and commercialization of inhalation products, including metered dose inhalers, inhalation powders, nasal sprays and blow-fill-seal products. The company has established research and manufacturing facilities to advance its product development. Founded by seasoned industry experts and entrepreneurs from the US pharmaceutical industry, CF PharmTech also provides CDMO services. It intends to use new financing to expedite submission of its product pipeline for regulatory approvals in China and abroad and to expand its CDMO services to international clients. The company raised $65M in a Series D financing to support these plans.

Participated · Series B · Jul 2018

Adlai Nortye is a China-based, clinical-stage biopharmaceutical company focused on developing immuno-oncology medicines. The company announced the completion of nearly $100 million in a Series C round of financing. The article identifies the raise as a Series C but does not specify the financing instrument beyond that round type. No participating investors or syndicate details were disclosed in the article. The report also does not provide information on prior funding rounds, founding year, revenue, users, or intended use of proceeds. The financing announcement was reported as having been made on Monday. Adlai Nortye Biopharma is a Hangzhou, China–based clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer treatments with a primary concentration on immuno-oncology. Led by CEO Carsten Lu, the company is advancing a pipeline of more than 10 diverse product candidates. It has two clinical-stage immune-oncology programs: Reolysin, an intravenously delivered immuno-oncolytic virus for solid tumors, and AN0025, a first-in-class EP4 antagonist. Reolysin is ready to enter a Phase III study and has received FDA Fast Track designation to expedite development and review. AN0025 is currently in a global Phase Ib trial. The company recently strengthened its financial position by completing a $53M Series B financing.

Led · Equity · Jun 2018

Mevion develops and sells compact proton therapy systems, including the HYPERSCAN™ pencil beam scanning solution that uses the Adaptive Aperture™ proton MLC. The company positions HYPERSCAN as a breakthrough in proton therapy and already has clinical use at MedStar Georgetown University Hospital, with installations at an NCI‑Designated Cancer Center in the U.S. and the MAASTRO Clinic in the Netherlands. Mevion reports strong commercial interest in the United States and Europe and is negotiating additional units in Asia, with two additional centers in final design. The $150 million financing will be used to further distance Mevion’s technological leadership, expand manufacturing capacity to meet increased interest, and support expansion into emerging markets and the Asia Pacific region. The transaction also clears existing debt and optimizes the shareholder structure. The new and existing investor group collectively manages over $10 billion in assets, providing a long‑term capital base. Mevion Medical Systems is a leading provider of proton therapy systems whose flagship product is the MEVION S250, the only modular single‑room proton therapy system currently on the market. The MEVION S250 delivers targeted radiation therapy at a fraction of the size, operating costs and energy use of legacy systems, with a single‑room footprint of about 2,000 sq. ft. and high operational efficiency. Mevion has installed systems at Barnes‑Jewish Hospital, Ackerman Cancer Center, and Robert Wood Johnson University Hospital and achieved rapid patient ramp‑up (first 100 patients in 11 months; ACC reached 350 patients/year in under three months; RWJ treated its first patient less than four weeks after ACC). The company is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan. Mevion announced an investment agreement for up to $200 million to accelerate worldwide expansion and to increase manufacturing capacity and global service capability to support new installations in the U.S., China and internationally. Concurrent with the investment, Mevion and the lead investors will form a joint venture in China to produce, sell and service proton therapy systems for the Chinese market. Mevion Medical Systems develops and supplies the MEVION S250, a single-room proton therapy system designed to deliver precise radiation with a reduced size and lower implementation cost compared with legacy proton systems. The MEVION S250 preserves the clinical benefits of traditional proton therapy while offering improved reliability, efficient clinical workflow, and a footprint similar to modern X-ray radiation therapy devices. The system is FDA-cleared for clinical use and the first MEVION S250 is installed at the S. Lee Kling Center for Proton Therapy at Barnes Jewish Hospital/Washington University Medical Center, currently undergoing clinical acceptance and commissioning. Mevion reports five centers under installation and construction and more than a dozen centers under planning, positioning the company for wider deployment. The company says its technology makes proton therapy more accessible and practical for hospitals and patients, including pediatric and high‑risk cases. To support this expansion, Mevion has raised additional capital to accelerate deployment of the MEVION S250 in the U.S. and internationally. Mevion Medical Systems is the developer of the MEVION S250 Proton Therapy System, a compact proton beam radiation device powered by a TriNiobium Core designed to reduce cost, size and complexity compared with traditional proton systems. The company says the S250 preserves the treatment benefits of proton therapy while improving accessibility and practicality for wider clinical deployment. Mevion has delivered its first system and has two additional systems under installation. The MEVION S250 had not yet been cleared by the U.S. FDA for clinical use at the time of the announcement. The company announced a $45 million investment to accelerate manufacturing and worldwide deployment of the S250. Mevion was founded in 2004 and is headquartered in the Boston metropolitan area, with international offices in the United Kingdom and Japan.

Participated · Series A · May 2018

Ansun Biopharma is a Chinese biotechnology company. It announced completion of a 56 million yuan (about $80 million) Series B financing. The round was led by a cohort of venture capital firms including Oceanpine Capital, Junson Capital Company Limited and KIP. The article does not describe the company's specific products, pipeline, or therapeutic focus. It also does not disclose use of proceeds or operating metrics such as revenue or user counts. No founding year or past funding rounds are mentioned in the article. Ansun BioPharma is a clinical-stage biopharmaceutical company focused on developing DAS181, a potentially first‑in‑class broad‑spectrum antiviral biologic for respiratory viral infections including influenza, parainfluenza, and metapneumovirus. The company is advancing DAS181 through clinical development and is working with the U.S. FDA to plan and implement a Phase 3 trial of DAS181 for parainfluenza infection in hospitalized and immunocompromised patients. DAS181 has received Breakthrough Designation and Fast Track designation from the U.S. FDA for this indication. Ansun intends to use the proceeds from its recent financing to support the planned Phase 3 clinical trial. The company is led by interim CEO Dr. Nancy Chang. Ansun is based in San Diego, CA.

Led · Series A · Mar 2018

JW Therapeutics, founded in 2016 by Juno Therapeutics and WuXi AppTec Group, is a Shanghai-based clinical-stage biopharmaceutical company focused on cell-based therapy technologies. The company has initiated development of its first CD19-directed investigational therapy, JWCAR029, a CAR-T being studied for B‑cell malignancies with an initial focus on relapsed and refractory DCBCL. JWCAR029 has moved into clinical phase and its IND was accepted by the China Food and Drug Administration (CFDA). JW Therapeutics has built a fully validated clinical GMP facility aligned with global QMS standards and assembled a leadership team of seasoned biotech/pharma executives led by CEO Hans Bishop. The company completed a $90M Series A financing and will use the proceeds to further advance the JWCAR029 clinical program and develop a broader therapeutic pipeline. JW Therapeutics also plans to build a new commercial manufacturing facility.